Next Century Growth Investors’s Vanda Pharmaceuticals VNDA Stock Holding History

Next Century Growth Investors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-338,102	Closed	-$4.84M	–	208
2014 Q4	$4.84M	Buy	338,102 +95,151	+39%	+$1.13M	0.17%	136
2014 Q3	$2.52M	Buy	242,951 +121,491	+100%	+$1.59M	0.09%	168
2014 Q2	$1.97M	Buy	+121,460	New	+$1.62M	0.06%	170

Other funds holding VNDA

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Next Century Growth Investors's VNDA Position: Q1 2015 in Review

Next Century Growth Investors sold out of Vanda Pharmaceuticals (VNDA) in Q1 2015, closing a stake of 338,102 shares — an estimated $4.84M sold.

Next Century Growth Investors first reported a position in VNDA in Q2 2014 and held it in 3 quarters. The position peaked at $4.84M in Q4 2014. 110 funds tracked by Wall St. Rank hold VNDA as of Q1 2015.

Next Century Growth Investors reported no remaining Vanda Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Next Century Growth Investors sold 338,102 Vanda Pharmaceuticals shares in Q1 2015, an estimated $4.84M.
Next Century Growth Investors first reported a position in Vanda Pharmaceuticals in Q2 2014 and held it in 3 quarters.
Next Century Growth Investors's Vanda Pharmaceuticals position peaked at $4.84M in Q4 2014.
110 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2015.

Based on Next Century Growth Investors's 13F filing for Q1 2015, filed 14 May 2015.